ABVC BioPharma ABVC Stock
ABVC BioPharma Price Chart
ABVC BioPharma ABVC Financial and Trading Overview
| ABVC BioPharma stock price | 1.28 USD |
| Previous Close | 1.41 USD |
| Open | 1.38 USD |
| Bid | 0.99 USD x 200 |
| Ask | 1.62 USD x 200 |
| Day's Range | 1.26 - 1.4 USD |
| 52 Week Range | 0.88 - 5.48 USD |
| Volume | 144.6K USD |
| Avg. Volume | 102.22K USD |
| Market Cap | 35.36M USD |
| Beta (5Y Monthly) | 0.422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ABVC Valuation Measures
| Enterprise Value | 38.95M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0909092 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.1627908 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.865 |
Trading Information
ABVC BioPharma Stock Price History
| Beta (5Y Monthly) | 0.422 |
| 52-Week Change | -17.57% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 5.48 USD |
| 52 Week Low | 0.88 USD |
| 50-Day Moving Average | 1.17 USD |
| 200-Day Moving Average | 2.1 USD |
ABVC Share Statistics
| Avg. Volume (3 month) | 102.22K USD |
| Avg. Daily Volume (10-Days) | 146.28K USD |
| Shares Outstanding | 26M |
| Float | 20.44M |
| Short Ratio | 3.64 |
| % Held by Insiders | 18.56% |
| % Held by Institutions | 3.14% |
| Shares Short | 272.68K |
| Short % of Float | 1.28% |
| Short % of Shares Outstanding | 1.05% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.0060% |
| Return on Equity (ttm) | -87.78% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -8006634 USD |
| Net Income Avi to Common (ttm) | -8626721 USD |
| Diluted EPS (ttm) | -0.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 202.51K USD |
| Total Cash Per Share (mrq) | 0.008 USD |
| Total Debt (mrq) | 2.73M USD |
| Total Debt/Equity (mrq) | 21.29 USD |
| Current Ratio (mrq) | 0.12 |
| Book Value Per Share (mrq) | 0.43 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3340709 USD |
| Levered Free Cash Flow (ttm) | 1.16M USD |
Profile of ABVC BioPharma
| Country | United States |
| State | CA |
| City | Fremont |
| Address | 44370 Old Warm Springs Boulevard |
| ZIP | 94538 |
| Phone | 510 668 0881 |
| Website | https://www.abvcpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 16 |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Q&A For ABVC BioPharma Stock
What is a current ABVC stock price?
ABVC BioPharma ABVC stock price today per share is 1.28 USD.
How to purchase ABVC BioPharma stock?
You can buy ABVC shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ABVC BioPharma?
The stock symbol or ticker of ABVC BioPharma is ABVC.
Which industry does the ABVC BioPharma company belong to?
The ABVC BioPharma industry is Biotechnology.
How many shares does ABVC BioPharma have in circulation?
The max supply of ABVC BioPharma shares is 26M.
What is ABVC BioPharma Price to Earnings Ratio (PE Ratio)?
ABVC BioPharma PE Ratio is now.
What was ABVC BioPharma earnings per share over the trailing 12 months (TTM)?
ABVC BioPharma EPS is -0.39 USD over the trailing 12 months.
Which sector does the ABVC BioPharma company belong to?
The ABVC BioPharma sector is Healthcare.
ABVC BioPharma ABVC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}